EP Patent

EP2861233A1 — Transdermal hormone replacement therapies

Assigned to TherapeuticsMD Inc · Expires 2015-04-22 · 11y expired

What this patent protects

Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.

USPTO Abstract

Hormone replacement therapies are provided comprising solubilized progesterone alone and optionally with an estrogen, cyclic/sequential and continuous-combined dosing, and administered via transdermal HRT delivery systems.

Drugs covered by this patent

Patent Metadata

Patent number
EP2861233A1
Jurisdiction
EP
Classification
—
Expires
2015-04-22
Drug substance claim
No
Drug product claim
No
Assignee
TherapeuticsMD Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.